Essentials
- •
Delayed treatment with tranexamic acid results in loss of efficacy and poor outcomes.
- •
Increasing urokinase activity may account for adverse effects of late tranexamic acid treatment.
- •
Urokinase + tranexamic acid produces plasmin in plasma or blood and disrupts clotting.
- •
α2‐Antiplasmin consumption with ongoing fibrinolysis increases plasmin‐induced coagulopathy.